JP2011503210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503210A5 JP2011503210A5 JP2010534263A JP2010534263A JP2011503210A5 JP 2011503210 A5 JP2011503210 A5 JP 2011503210A5 JP 2010534263 A JP2010534263 A JP 2010534263A JP 2010534263 A JP2010534263 A JP 2010534263A JP 2011503210 A5 JP2011503210 A5 JP 2011503210A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidin
- yloxy
- alkyl
- phenyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydrate Chemical class 0.000 claims description 257
- 150000001875 compounds Chemical class 0.000 claims description 123
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 125000004122 cyclic group Chemical group 0.000 claims description 19
- 150000001204 N-oxides Chemical class 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000005605 benzo group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 150000003857 carboxamides Chemical class 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- MCLGXPUTSWJSRB-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)-n-[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]piperidin-4-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2C=C3CCC(C3=CC=2)NC2CCN(CC=3C=CN=CC=3)CC2)CC1 MCLGXPUTSWJSRB-UHFFFAOYSA-N 0.000 claims description 2
- IIYPLRFMIACDPN-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]piperidin-4-amine Chemical compound C1=CC(F)=CC=C1CN1CCC(NC2C3=CC=C(OC4CCN(CC4)C=4C=CC(=CC=4)C(F)(F)F)C=C3CC2)CC1 IIYPLRFMIACDPN-UHFFFAOYSA-N 0.000 claims description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- GCWSPRDNKSEPKJ-UHFFFAOYSA-N CC1C=CC(=CN1C2CCN(CC2)CC3=CN(C=N3)C(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)OC7CCN(CC7)C8=CC=C(C=C8)C(F)(F)F Chemical compound CC1C=CC(=CN1C2CCN(CC2)CC3=CN(C=N3)C(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)OC7CCN(CC7)C8=CC=C(C=C8)C(F)(F)F GCWSPRDNKSEPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 2
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 2
- ZTFZEMAQQLKFEQ-UHFFFAOYSA-N n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]-6-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxypyridine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2N=C(C=CC=2)C(=O)NC2CCN(CC=3C=CN=CC=3)CC2)CC1 ZTFZEMAQQLKFEQ-UHFFFAOYSA-N 0.000 claims description 2
- JGGUDZHAKXSMBF-UHFFFAOYSA-N n-[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]piperidin-4-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2C=C3CCC(C3=CC=2)NC2CCNCC2)CC1 JGGUDZHAKXSMBF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- KXNHURZRBCWTFV-UHFFFAOYSA-N tert-butyl 4-[[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1C2=CC=C(OC3CCN(CC3)C=3C=CC(=CC=3)C(F)(F)F)C=C2CC1 KXNHURZRBCWTFV-UHFFFAOYSA-N 0.000 claims description 2
- RTJCPJPIPFHECW-UHFFFAOYSA-N tert-butyl 4-[[6-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxypyridin-3-yl]sulfonylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NS(=O)(=O)C(C=N1)=CC=C1OC1CCN(C=2C=CC(=CC=2)C(F)(F)F)CC1 RTJCPJPIPFHECW-UHFFFAOYSA-N 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- DFWJSMFBORLYJK-UHFFFAOYSA-N O=C(C1=CC(C=CC=C2)=C2S1)NOC(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 Chemical compound O=C(C1=CC(C=CC=C2)=C2S1)NOC(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 DFWJSMFBORLYJK-UHFFFAOYSA-N 0.000 claims 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- BYHWWOPUEYHTSB-UHFFFAOYSA-N 4-[[4-[[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]amino]piperidin-1-yl]methyl]benzonitrile Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2C=C3CCC(C3=CC=2)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 BYHWWOPUEYHTSB-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98872107P | 2007-11-16 | 2007-11-16 | |
| US60/988,721 | 2007-11-16 | ||
| US99055807P | 2007-11-27 | 2007-11-27 | |
| US99055407P | 2007-11-27 | 2007-11-27 | |
| US60/990,558 | 2007-11-27 | ||
| US60/990,554 | 2007-11-27 | ||
| US99118907P | 2007-11-29 | 2007-11-29 | |
| US60/991,189 | 2007-11-29 | ||
| US1392407P | 2007-12-14 | 2007-12-14 | |
| US61/013,924 | 2007-12-14 | ||
| PCT/US2008/083801 WO2009065131A1 (en) | 2007-11-16 | 2008-11-17 | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503210A JP2011503210A (ja) | 2011-01-27 |
| JP2011503210A5 true JP2011503210A5 (enExample) | 2012-12-20 |
| JP5544296B2 JP5544296B2 (ja) | 2014-07-09 |
Family
ID=40352415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534263A Expired - Fee Related JP5544296B2 (ja) | 2007-11-16 | 2008-11-17 | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8119809B2 (enExample) |
| EP (1) | EP2231600B1 (enExample) |
| JP (1) | JP5544296B2 (enExample) |
| KR (1) | KR101573091B1 (enExample) |
| CN (1) | CN101910131B (enExample) |
| AU (3) | AU2008322426C1 (enExample) |
| BR (1) | BRPI0820171B8 (enExample) |
| CA (1) | CA2705947C (enExample) |
| EA (1) | EA019509B1 (enExample) |
| ES (1) | ES2552733T3 (enExample) |
| IL (1) | IL205624A (enExample) |
| MX (2) | MX2010005298A (enExample) |
| NZ (1) | NZ585298A (enExample) |
| WO (1) | WO2009065131A1 (enExample) |
| ZA (1) | ZA201003412B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| KR101573091B1 (ko) | 2007-11-16 | 2015-11-30 | 리겔 파마슈티칼스, 인크. | 대사성 장애를 위한 카르복스아미드, 술폰아미드 및 아민 화합물 |
| CA2707047C (en) * | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| CA2722139C (en) * | 2008-04-23 | 2017-04-11 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| HRP20150355T1 (hr) | 2009-01-12 | 2015-06-19 | Pfizer Limited | Sulfonamidni derivati |
| NZ594556A (en) | 2009-01-28 | 2013-11-29 | Rigel Pharmaceuticals Inc | Carboxamide compounds and methods for using the same |
| MX2011013016A (es) | 2009-06-05 | 2012-04-20 | Link Medicine Corp | Derivados de aminopirrolidinona y usos de los mismos. |
| CN102666485A (zh) * | 2009-09-21 | 2012-09-12 | 霍夫曼-拉罗奇有限公司 | 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011115106A1 (ja) * | 2010-03-16 | 2011-09-22 | 国立大学法人 東京大学 | 擬似運動療法のための医薬 |
| WO2011123681A1 (en) * | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| TW201211053A (en) * | 2010-05-10 | 2012-03-16 | Nissan Chemical Ind Ltd | Spiro compound and drug for activating adiponectin receptor |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| EP2590972B1 (en) | 2010-07-09 | 2015-01-21 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| CA2806341C (en) | 2010-07-29 | 2020-03-24 | Rigel Pharmaceuticals, Inc. | Ampk-activating heterocyclic compounds and methods for using the same |
| JP5769326B2 (ja) | 2010-10-19 | 2015-08-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒｈｏキナーゼ阻害薬 |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9409884B2 (en) * | 2012-02-01 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| JP6233855B2 (ja) * | 2012-08-08 | 2017-11-22 | ノバルティス・ティーアゲズントハイト・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｔｉｅｒｇｅｓｕｎｄｈｅｉｔ Ａｇ | 殺虫剤としての置換されたアジン類 |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| MX2020011652A (es) | 2013-07-31 | 2022-09-27 | Novartis Ag | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. |
| WO2015046595A1 (ja) | 2013-09-30 | 2015-04-02 | 国立大学法人東京大学 | アディポネクチン受容体活性化化合物 |
| EP3231802B1 (en) * | 2014-12-08 | 2021-05-05 | Jiangsu Hengrui Medicine Co., Ltd. | Pyridine-2-carboxamide derivatives, preparation method therefor and pharmaceutical uses thereof |
| EP3959205B1 (en) * | 2019-04-26 | 2025-11-12 | Merck Sharp & Dohme LLC | Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
| WO2022072397A1 (en) | 2020-09-30 | 2022-04-07 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8820115D0 (en) * | 1988-08-24 | 1988-09-28 | Ici Plc | Insecticidal compounds |
| US6137002A (en) * | 1993-07-22 | 2000-10-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| NZ331490A (en) | 1996-03-28 | 2000-06-23 | Glaxo Group Ltd | Pyrrolopyrrolone derivatives for the treatment or prophylaxis of inflammatory disease such as chronic bronchitis, obstructive pulmonary disease and asthma |
| GB9715584D0 (en) | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
| DE19738615A1 (de) * | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| EP1107758A2 (en) | 1998-08-28 | 2001-06-20 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| DK1218380T3 (da) * | 1999-10-08 | 2004-03-15 | Gruenenthal Gmbh | Bicykliske imidazo-3-yl-aminoderivater substitueret i seksledsringen |
| US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| US7273868B2 (en) * | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE10050663A1 (de) * | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| WO2002089749A2 (en) | 2001-05-10 | 2002-11-14 | Abbott Gmbh & Co.Kg | Arylsulfonamide ethers, and methods of use thereof |
| BR0212123A (pt) | 2001-08-24 | 2004-07-20 | Upjohn Co | 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças |
| EP1425286B1 (en) | 2001-09-12 | 2007-02-28 | Pharmacia & Upjohn Company LLC | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
| CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| MXPA04007083A (es) * | 2002-02-20 | 2004-10-29 | Upjohn Co | Compuestos azabiciclicos para el tratamiento de enfermedades. |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| AU2003254157A1 (en) * | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| EP1569646A2 (en) | 2002-12-13 | 2005-09-07 | Smithkline Beecham Corporation | Piperidine derivatives as ccr5 antagonists |
| US7208491B2 (en) * | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| GB0314054D0 (en) | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| JP2007516256A (ja) | 2003-12-12 | 2007-06-21 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US20050234095A1 (en) * | 2004-03-25 | 2005-10-20 | Wenge Xie | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| CN1960727B (zh) * | 2004-06-02 | 2011-02-16 | 霍夫曼-拉罗奇有限公司 | 用作组胺-3受体的配体的萘衍生物 |
| CN1972926B (zh) * | 2004-06-21 | 2011-02-16 | 霍夫曼-拉罗奇有限公司 | 作为组胺受体拮抗剂的吲哚衍生物 |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| ATE517882T1 (de) | 2004-10-19 | 2011-08-15 | Hoffmann La Roche | Chinolinderivate |
| AU2005300150A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| CN101098870B (zh) | 2004-11-08 | 2010-11-03 | 万有制药株式会社 | 新型稠环咪唑衍生物 |
| US20080125432A1 (en) | 2004-12-01 | 2008-05-29 | Devgen Nv | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family |
| BRPI0517211B8 (pt) | 2004-12-17 | 2021-05-25 | Glenmark Pharmaceuticals Sa | composto, composição farmacêutica e seu uso. |
| EP1838312A4 (en) | 2004-12-17 | 2010-01-20 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| US20060187891A1 (en) | 2005-02-24 | 2006-08-24 | Jussi-Pekka Sairanen | Provision of services in a communication system |
| CA2599987A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| US7893267B2 (en) | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| EP1863810A4 (en) | 2005-03-22 | 2010-03-31 | Astrazeneca Ab | NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| JP2009500419A (ja) | 2005-07-05 | 2009-01-08 | アリックス セラピューティクス、インコーポレイテッド | 立体異性体のピリジル及びピリドニル化合物並びに消化管障害及び中枢神経系障害の治療方法 |
| CA2622677A1 (en) * | 2005-09-23 | 2007-04-05 | Richard Schumacher | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| KR101047204B1 (ko) * | 2005-11-30 | 2011-07-06 | 에프. 호프만-라 로슈 아게 | Ｈ3 조절제로서 사용하기 위한1,1-다이옥소-싸이오모폴린일 인돌일 메탄온 유도체 |
| ES2342979T3 (es) * | 2005-11-30 | 2010-07-20 | F. Hoffmann-La Roche Ag | Derivados de indol-2-carboxamida sustituidos en 5. |
| CN101316840B (zh) * | 2005-11-30 | 2012-08-08 | 霍夫曼-拉罗奇有限公司 | 1,5-取代的吲哚-2-基酰胺衍生物 |
| WO2007075688A2 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine h3 antagonists |
| JP2009524689A (ja) | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
| TW200738711A (en) | 2006-01-25 | 2007-10-16 | Smithkline Beecham Corp | Chemical compounds |
| WO2007098086A2 (en) * | 2006-02-17 | 2007-08-30 | Avalon Pharmaceuticals | Hydroxypiperidine derivatives and uses thereof |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| NL2000581C2 (nl) | 2006-04-20 | 2008-01-03 | Pfizer Prod Inc | Aangecondenseerde fenylamidoheterocyclische verbindingen. |
| WO2007125405A2 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| EP2032566A4 (en) | 2006-06-12 | 2009-07-08 | Merck Frosst Canada Ltd | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| CA2654098A1 (en) | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| TW200821303A (en) | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| EP2079694B1 (en) * | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| JP2010527915A (ja) * | 2007-04-26 | 2010-08-19 | アバロン ファーマシューティカルズ，インコーポレイテッド | 多重環化合物及びその用途 |
| SG183049A1 (en) * | 2007-07-20 | 2012-08-30 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| KR101573091B1 (ko) | 2007-11-16 | 2015-11-30 | 리겔 파마슈티칼스, 인크. | 대사성 장애를 위한 카르복스아미드, 술폰아미드 및 아민 화합물 |
| CA2707047C (en) * | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| EA018703B1 (ru) * | 2008-04-07 | 2013-10-30 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности gpr119 |
| CA2722139C (en) | 2008-04-23 | 2017-04-11 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| JP2010090067A (ja) * | 2008-10-09 | 2010-04-22 | Taisho Pharmaceutical Co Ltd | 含窒素複素環誘導体 |
-
2008
- 2008-11-17 KR KR1020107013166A patent/KR101573091B1/ko not_active Expired - Fee Related
- 2008-11-17 ES ES08848677.4T patent/ES2552733T3/es active Active
- 2008-11-17 EA EA201070619A patent/EA019509B1/ru not_active IP Right Cessation
- 2008-11-17 US US12/272,581 patent/US8119809B2/en active Active
- 2008-11-17 NZ NZ585298A patent/NZ585298A/xx not_active IP Right Cessation
- 2008-11-17 MX MX2010005298A patent/MX2010005298A/es active IP Right Grant
- 2008-11-17 MX MX2014005186A patent/MX382569B/es unknown
- 2008-11-17 CA CA2705947A patent/CA2705947C/en active Active
- 2008-11-17 EP EP08848677.4A patent/EP2231600B1/en not_active Not-in-force
- 2008-11-17 BR BRPI0820171A patent/BRPI0820171B8/pt not_active IP Right Cessation
- 2008-11-17 JP JP2010534263A patent/JP5544296B2/ja not_active Expired - Fee Related
- 2008-11-17 AU AU2008322426A patent/AU2008322426C1/en not_active Ceased
- 2008-11-17 WO PCT/US2008/083801 patent/WO2009065131A1/en not_active Ceased
- 2008-11-17 CN CN200880124960.1A patent/CN101910131B/zh not_active Expired - Fee Related
-
2010
- 2010-05-09 IL IL205624A patent/IL205624A/en active IP Right Grant
- 2010-05-14 ZA ZA2010/03412A patent/ZA201003412B/en unknown
-
2012
- 2012-01-11 US US13/348,380 patent/US8569340B2/en not_active Expired - Fee Related
-
2013
- 2013-10-14 US US14/053,325 patent/US9174964B2/en active Active
-
2014
- 2014-05-13 AU AU2014202572A patent/AU2014202572B2/en not_active Ceased
-
2017
- 2017-04-27 AU AU2017202766A patent/AU2017202766B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503210A5 (enExample) | ||
| JP2011506480A5 (enExample) | ||
| JP2010514788A5 (enExample) | ||
| ES2552733T3 (es) | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos | |
| JP2011527665A5 (enExample) | ||
| CA2798360C (en) | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | |
| US20040192701A1 (en) | Phenlypyridine carbonyl piperazine derivative | |
| JP4719745B2 (ja) | カリウムチャンネル阻害剤 | |
| JP2013532692A5 (enExample) | ||
| JP2012512255A5 (enExample) | ||
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| TW200823188A (en) | Certain chemical entities, compositions, and methods | |
| KR20180073685A (ko) | 신경계 질환을 치료하기 위한, 무스카린성 수용체 4 (m4) 길항제로서의 n-[2-(1-벤질피페리딘-4-일)에틸]-4-(피라진-2-일)-피페라진-1-카르복스아미드 유도체 및 관련된 화합물 | |
| RU2008116313A (ru) | Диарилминсодержащие соединения, композиции и их примеение в качестве модуляторов рецепторов с-кit | |
| JP2006298893A5 (enExample) | ||
| KR20120049940A (ko) | 키나제 억제제로서의 헤테로아릴 화합물 | |
| JP2010513304A5 (enExample) | ||
| TWI455715B (zh) | ４－（４－氰基－２－硫基芳基）二氫嘧啶酮類及其用途 | |
| RU2005122932A (ru) | Производные бензазепина для лечения неврологических нарушений | |
| JP2014501269A5 (enExample) | ||
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| KR20120092586A (ko) | 증식성 질환의 치료에 유용한 비피리딘 | |
| KR20120076352A (ko) | 증식성 질환의 치료에 유용한 피라지닐피리딘 | |
| JP2007532596A5 (enExample) | ||
| KR102217285B1 (ko) | 신규한 3,4-다이하이드로-2h-이소퀴놀린-1-온 및 2,3-다이하이드로-이소인돌-1-온 화합물 |